Academic history
Arun Azad, MBBS, FRACP, PhD, is a Medical Oncologist and Translational Researcher specializing in prostate cancer at the Peter MacCallum Cancer Centre, Melbourne, Australia. He is also Co-Principal Investigator for the Movember/MRFF UpFrontPSMA Prostate Cancer Research Alliance and Chair of the ANZUP Cancer Trials Group Translational Research Sub-Committee. Dr Azad earned his degree in Medicine from the University of Melbourne, Melbourne, Australia before completing his PhD in Oncology and Cancer Biology at the same institution. After completing his medical oncology training and PhD, he pursued a two-year fellowship at the British Columbia Cancer Agency and Vancouver Prostate Centre, Vancouver, Canada, focusing on genomic profiling of circulating cell-free DNA in advanced prostate cancer.
Speaking on clinical research investigating prostate cancer
After completing his fellowship in 2015, Dr Azad returned to Australia and has now established himself as a prominent figure in prostate cancer research, with over 100 publications and significant funding, including an NHMRC Investigator Grant. His current research interests focus on the development and validation of circulating biomarker assays for advanced prostate cancer, aiming to enhance precision medicine approaches.
Dr Azad has been directly involved in several pivotal clinical trials, such as the ARCHES study, which investigated the addition of enzalutamide to standard care for metastatic hormone-sensitive prostate cancer, and the TALAPRO-2 study, which investigated the efficacy and safety of talazoparib, a potent PARP inhibitor, in combination with enzalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC). Additionally, he has contributed to the Movember/MRFF UpFrontPSMA Prostate Cancer Research Alliance, which explores the use of PSMA PET imaging to guide treatment decisions.
Sorry, no posts matched your criteria.
